Our results suggest that targeting COX-2 prior to the anti-CTLA-4 immunotherapy scheme, which takes advantage of NK cells cytotoxic capacity, may be a promising strategy to improve the effectiveness of immunotherapy for ovarian cancer patients. The gene discussed is PTGS2; the disease is ovarian carcinoma.